Table 3.

New infectious virus particle production at 16h p.i. after 48hr pre-treatment with JAK Inh. I

PDA Cells	Treatmenta	Yieldb	Ratioc
AsPC-1	VSV	8.4×107	1
	VSV + 0.5 μM JAK Inh. I	4.2×108	5
	VSV + 2.5 μM JAK Inh. I	2.6×108	3
CFPAC	VSV	1.3×106	1
	VSV+ 0.5 μM JAK Inh. I	2.6×107	20
	VSV + 2.5 μM JAK Inh. I	2.1×107	16
HPAC	VSV	2.6×106	1
	VSV + 0.5 μM JAK Inh. I	3.1×107	12
	VSV + 2.5 μM JAK Inh. I	7.9×106	3
HPAF-II	VSV	2.0×104	1
	VSV + 0.5 μM JAK Inh. I	1.3×106	64
	VSV + 2.5 μM JAK Inh. I	5.2×106	256
Hs766T	VSV	4.1×104	1
	VSV + 0.5 μM JAK Inh. I	2.1×107	512
	VSV + 2.5 μM JAK Inh. I	1.0×107	256
MIA PaCa-2	VSV	4.2×108	1
	VSV + 0.5 μM JAK Inh. I	5.0×108	1.2
	VSV + 2.5 μM JAK Inh. I	2.1×108	0.5
Suit2	VSV	2.1×108	1
	VSV + 0.5 μM JAK Inh. I	1.3×108	0.6
	VSV + 2.5 μM JAK Inh. I	8.4×107	0.4
HPDE	VSV	6.1×104	1
	VSV + 0.5 μM JAK Inh. I	1.3×108	2048
	VSV + 2.5 μM JAK Inh. I	1.3×108	2048

^a“VSV” indicates VSV-Δ M51-GFP

^bVirus was collected from the indicated cell line and titer was determined on BHK-21 cells

^cRatio of virus yield on JAK Inh. I treated cells to mock treated cells